Treatment of Philadelphia Chromosome–Positive B-Cell Acute Lymphoblastic Leukemia in a Patient With Li-Fraumeni Syndrome (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-1157; "Treatment followed a chemotherapy-sparing approach modeled on the Foà/D-ALBA regimen: steroid prephase, dasatinib plus blinatumomab induction, and intrathecal methotrexate and hydrocortisone for CNS prophylaxis...At month 4, dasatinib was discontinued due to a left pleural effusion and replaced with asciminib (off-label use); ponatinib was avoided given the effusion history, and imatinib was felt to offer insufficient potency... To our knowledge, this is the first reported case of Ph+ B-cell ALL in a patient with LFS. It illustrates that a chemotherapy-sparing TKI-bispecific backbone, with substitution of asciminib for dasatinib intolerance, can achieve deep molecular remission while limiting genotoxic exposure in this high-risk population. ALL: acute lymphoblastic leukemia, BCR-ABL1: breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1, CAR-T: chimeric antigen receptor T-cell, CD: cluster of differentiation, CNS: central nervous..."
Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
|
|
Abhinav Anand Vayal Veettil MD; Rafaella Litvin MD; Anjali Advani MD; Abhay Singh MD,MPH
|